NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx.
The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing.